文献速递认知障碍与痴呆帕金森病与运动障碍

血清p-tau217可预测特发性快速眼动睡眠行为障碍患者的认知损害

Serum p-tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder.
PubMed 文献 · Ann Neurol · 2025-11-28

该研究在300例多导睡眠图确诊的特发性快速眼动睡眠行为障碍(iRBD)患者中评估血清p-tau217和神经丝轻链(NfL)对认知损害或转化为痴呆的预测价值。结果显示,血清p-tau217可区分转化为帕金森病伴认知损害(PD-CI)或路易体痴呆(DLB)的患者,其最高四分位者转化风险为最低四分位的8倍,而NfL预测认知损害价值有限。

要点

  • 血清p-tau217可区分iRBD转化为PD-CI或DLB的患者与认知正常的转化者。
  • p-tau217最高四分位者转化为PD-CI或DLB的风险是最低四分位的8倍。
  • NfL与认知或运动评分不相关,但在转化为多系统萎缩(MSA)的iRBD患者中显著升高。

核心结论

  • 血清p-tau217而非NfL是iRBD认知损害的有用生物标志物,可整合入多模态预后指标用于风险分层。

研究设计与样本

  • 研究纳入4个多导睡眠图确诊的iRBD队列共300例,其中转化为帕金森病51例、路易体痴呆22例、多系统萎缩5例。
  • 采用电化学发光法测量血清p-tau217和NfL水平。

主要发现

  • iRBD伴认知损害(蒙特利尔认知评估<26或亚临床帕金森综合征)者血清p-tau217水平升高。
  • p-tau217区分转化为PD-CI或DLB者与认知正常的PD转化者的AUC为0.82(95%CI 0.70-0.93)。
  • p-tau217区分转化为PD-CI或DLB者与认知正常的iRBD未转化者的AUC为0.83(95%CI 0.77-0.89)。
  • NfL与认知或运动评分不相关,仅轻微改善p-tau217的预测性能(AUC=0.85,95%CI 0.78-0.92),但在转化为MSA的iRBD患者中显著升高。
  • p-tau217最高四分位者转化为PD-CI或DLB的风险是最低四分位的8倍(HR=8.30,95%CI 2.49-27.65)。

临床怎么用

  • 对iRBD患者可检测血清p-tau217以辅助分层认知损害及转化为PD-CI或DLB的风险。
  • NfL不推荐单独用于预测iRBD认知损害,但可考虑用于提示转化为MSA的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Assess the performance of serum phosphorylated tau 217 (p-tau217) and neurofilament light chain (NfL) in predicting risk of cognitive impairment or phenoconversion to dementia in individuals with iRBD. METHODS: We measured serum p-tau217 and NfL levels by electrochemiluminescence across 4 polysomnographically confirmed iRBD cohorts (n = 300), including individuals who phenoconverted to Parkinson's disease (PD) (n = 51), dementia with Lewy bodies (DLB) (n = 22), and multiple system atrophy (MSA) (n = 5). RESULTS: Serum p-tau217 levels were increased in individuals with iRBD and cognitive impairment (CI) on testing defined as Montreal Cognitive Assessment <26 or subthreshold parkinsonism. p-Tau217 differentiated individuals with iRBD who developed PD with CI (PD-CI) or DLB from PD phenoconverters with normal cognition (area under curve [AUC] = 0.82; 95% confidence interval, 0.70-0.93) and from iRBD non-phenoconverters with normal cognition (AUC = 0.83; 95% confidence interval, 0.77-0.89). NfL levels did not correlate with cognitive or motor scores and marginally improved p-tau217 performance (AUC = 0.85; 95% confidence interval, 0.78-0.92), but were notably elevated in iRBD individuals who phenoconverted to MSA. Individuals with p-tau217 in the top quartile were 8 times more likely to phenoconvert to PD-CI or DLB compared to the bottom quartile (hazard ratio = 8.30; 95% confidence interval, 2.49-27.65). INTERPRETATION: Serum p-tau217, but not NfL, is a useful biomarker of cognitive impairment in iRBD that could be integrated into a multimodal prognostic indicator when stratifying risk of phenoconversion. ANN NEUROL 2026;99:912-921.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Yan S, Sahoo A, Zerenner T, et al. Serum p-tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder. Ann Neurol. 2025. PMID: 41312760. doi:10.1002/ana.78109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。